Visualizing real-time physiologic and molecular tumor response to targeted molecular agents and radiation, within the complex in situ host environment - in effect a wireless biopsy - provides a heretofore unseen window into cancer biology, guiding optimal, personalized patient care.
We aim to develop a versatile platform imaging the dynamic immune response within the patient?s tumor microenvironment. Here we introduce a first-in-class, fully implantable, wireless, microfabricated electronic-photonic platform for real-time in vivo tumor monitoring. This platform can be utilized with any tumor type as well as non-oncologic applications where biomarkers are essential. The platform will provide the full functionality of a fluorescence microscope, in a millimeter-scale implantable sensor. in vivo microscopy enables intratumoral fluorescent imaging, leveraging an armamentarium of existing targeted biologics unveiling both tumor biology within the complex host environment and early indicators of tumor response. We will detect and explore the role of the immune response at the site of disease dramatically increasing sensitivity while providing spatial localization - key to unlocking a systemic effect. Made possible by recent innovations in wireless power and data transfer, and unprecedented integration of high-speed circuits with photonics, these advances will unlock an entirely new paradigm of real- time response assessment enabling effective application of novel therapeutics and immunotherapy, customized to patient?s tumor biology.

Public Health Relevance

Visualizing real-time tumor response to immune checkpoint agents, within the complex in situ host environment - in effect a wireless biopsy - provides a heretofore unseen window into cancer biology, guiding optimal, personalized patient care. We leverage this approach to enable a new paradigm of cancer treatment whereby targeted molecular agents, radiation and IO therapy are rapidly iterated to elicit maximal response - achieving the ultimate goal of personalized medicine guided by each patient's unique tumor biology.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
NIH Director’s New Innovator Awards (DP2)
Project #
1DP2DE030713-01
Application #
10002722
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Shum, Lillian
Project Start
2020-09-10
Project End
2025-06-30
Budget Start
2020-09-10
Budget End
2025-06-30
Support Year
1
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118